In Vitro Cross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations

Documenti analoghi

• Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors
  di: Li, Zhufang, et al.
  Pubblicazione: (2013)
• The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1
  di: Smith, Robert A., et al.
  Pubblicazione: (2015)
• BMS-986001, an HIV Nucleoside Reverse Transcriptase Inhibitor, Does Not Degrade Mitochondrial DNA in Long-Term Primary Cultures of Cells Isolated from Human Kidney, Muscle, and Adipose Tissue
  di: Wang, Faye, et al.
  Pubblicazione: (2013)
• Abacavir versus other nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies for treatment of HIV infection
  di: Cruciani, Mario, et al.
  Pubblicazione: (2018)
• Ultra-Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse-Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI-Naive Patients
  di: Margeridon-Thermet, Severine, et al.
  Pubblicazione: (2009)